2025 Operational Highlights

Throughout 2025, Bone Biologics (BBLG) concentrated on crucial strategic priorities across development, operations, and corporate governance. The following milestones illustrate the company's commitment to enhancing its ongoing programs and ensuring organizational resilience:

• Extended rhNELL-1 Product Shelf Life: In December 2025, the Company announced that it successfully extended the validated shelf life of its lead product candidate, rhNELL-1, to 24 months, previously achieving 12- and 18-month stability milestones. This extension is expected to improve manufacturing efficiency, enhance supply-chain flexibility, and bolster clinical readiness.
• Strengthened Capital Position: Bone Biologics completed a registered public offering generating $5 million in gross proceeds during Q2 2025, providing necessary funding to advance clinical development activities, bolster intellectual property efforts, and support general corporate purposes.
• Expanded Intellectual Property Portfolio: The Company filed a U.S. patent application concerning its bone regeneration technology that leverages recombinant human NELL-1, further fortifying its proprietary platform.
• Maintained Nasdaq Listing Compliance: In June 2025, Bone Biologics regained compliance with Nasdaq’s minimum bid price requirement, ensuring continued access to public capital markets.
• Increased Investor Engagement: Management participated in the H.C. Wainwright 27th Annual Global Investment Conference and issued a detailed stockholder letter outlining advancements in clinical and operational initiatives.

Strategic Outlook for 2026

As Bone Biologics embarks on 2026, it aims to maintain its focus on advancing its clinical-stage programs while strengthening operational foundations. Key strategic objectives include:

• Clinical Development Progression: The company will continue advancing NB1, its rhNELL-1-based bone graft product candidate, with anticipated completion of patient enrollment in its first-in-human clinical trial and potential interim updates.
• Operational and Manufacturing Execution: Ongoing efforts will focus on regulatory readiness and future commercialization planning.
• Intellectual Property Strategy: The pursuit of relevant patent protections will enhance the long-term value of Bone Biologics' platform.
• Financial Discipline and Strategic Focus: The company intends to maintain prudent capital management while supporting scientific advancements and enhancing shareholder engagement.

About Bone Biologics

Founded to advance regenerative medicine for bone, Bone Biologics focuses on the development of innovative solutions for bone regeneration, particularly in spinal fusion. The Company is pursuing strategic partnerships that build upon prior research on the NELL-1 protein. In addition to its primary focus, Bone Biologics has rights to applications involving trauma and osteoporosis.

For additional information, visit www.bonebiologics.com.

Forward-Looking Statements

The statements contained in this report, particularly concerning Bone Biologics’ strategic plans and expected achievements for 2026, involve forward-looking ideas as defined by the Private Securities Litigation Reform Act of 1995. These statements entail risks and uncertainties that could cause actual outcomes to differ materially from anticipations. Essential documents and additional information regarding the Company's risks are available in the Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings.